Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of SSGJ-613 for prevention of acute gout flares during initiation of urate-lowering therapy
CTR20262655Phase 2Active
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SSGJ-613 in gout, sponsored by 3S Guojian Pharmaceutical. Started Sep 2026; status: active.
02
Drugs
SSGJ-613
03
Conditions
gout
Beyond the preview
Go deeper on CTR20262655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262655.